Moderna's mRNA Flu Vaccine Outperforms Standard Shots

benzinga.com/news/health-care/25/06/46168811/modernas-mrna-flu-vaccine-outperforms-standard-shots

Moderna, Inc. (NASDAQ:MRNA) on Monday revealed results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the company’s seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal…

This story appeared on benzinga.com, 2025-06-30 13:51:05.
The Entire Business World on a Single Page. Free to Use →